Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting, page-37

It was highlight point 2 that spoke to me ...

Patients with a higher level of T cell diversity inperipheral blood (pre-treatment) respond better to VAXINIA therapy, consistentwith the known mechanism of action of oncolytic virotherapies and their abilityto promote an anti-tumour T cell response.

This speaks to MoA and again basically proves that our virus is very effective.

We know that T-cell diversity is a positive as it helps immune defence in 2 ways ...

• it means the patient has a strong pool of efficient T cells (which will be used in the ‘attack’)

• and it is flexible enough to ‘short-circuit’ an attempt at mutation.

This data will inform future expansions.

As others have said ... the next data cut may be left to YF to unveil. Time will tell ... soon I think.

Just my quick thoughts.